title: Choice of modality with the use of high-performance membrane and evaluation for clinical effects.
abstract: The golden target for dialysis therapy should be to guarantee longer survival and to give a higher quality of life without dialysis-related complications. In order to achieve this target, the choice of dialysis modality and membrane is essential but we have not yet established what the best choice for a dialysis modality and membrane are. Generally, we choose a dialysis modality for better solute removal and better biocompatibility. In this issue we would like to propose that the patients' preference for dialysis therapy is a useful parameter in prescribing the dialysis modality. In our recent experience, chronic dialysis patients have had preferences on a dialysis modality and membrane, those being PMMA, EVAL, AN-69 and pre-dilution online HDF. These modalities could relieve them of uncomfortable dialysis-related symptoms such as insomnia, itchiness, irritability, and so on. Other characteristics of these modalities are of a nutritional advantage, a broad removal pattern of uremic toxins including low-molecular-weight protein and protein-bound uremic toxins, and good biocompatibility free from chemical components of dialysis membrane. In conclusion, patients' symptoms could be a useful parameter to choose a dialysis modality and membrane.
authors.affiliation: Yabuki Shima Clinic, Yamagata, Japan.
authors.forename: Ikuto
authors.initials: I
authors.lastname: Masakane
mesh_terms: D000180:Acrylic Resins; D000181:Acrylonitrile / Q000031:analogs & derivatives; D000686:Amyloidosis / Q000209:etiology / Q000517:prevention & control; D018771:Arthralgia / Q000209:etiology / Q000517:prevention & control; D001559:Benzhydryl Compounds; D001672:Biocompatible Materials; D017583:Hemodiafiltration / Q000295:instrumentation*; D006801:Humans; D008297:Male; D044342:Malnutrition / Q000209:etiology / Q000517:prevention & control; D008567:Membranes, Artificial; D008875:Middle Aged; D008970:Molecular Weight; D010636:Phenols / Q000737:chemistry; D019904:Polymethyl Methacrylate; D011145:Polyvinyls; D011205:Povidone / Q000737:chemistry; D011537:Pruritus / Q000209:etiology / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000009:adverse effects / Q000295:instrumentation*; D012709:Serum Albumin / Q000737:chemistry; D011795:Surveys and Questionnaires; D016019:Survival Analysis; D014511:Uremia / Q000150:complications / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D001613:beta 2-Microglobulin / Q000032:analysis; D000098826:Bisphenol A Compounds
chemical_list: D000180:Acrylic Resins; D000181:Acrylonitrile; D001559:Benzhydryl Compounds; D001672:Biocompatible Materials; D008567:Membranes, Artificial; D010636:Phenols; D019904:Polymethyl Methacrylate; D011145:Polyvinyls; D011205:Povidone; D012709:Serum Albumin; D001613:beta 2-Microglobulin; C020320:ethylene-vinyl alcohol copolymer; C016892:AN-69; C006780:bisphenol A; D000098826:Bisphenol A Compounds